Literature DB >> 26173982

Patient Cases: 1. A Patient with Apparent Compliance.

Pantelis A Sarafidis1.   

Abstract

Compliance with antihypertensive therapy decreases over time and as the number of pills increases. This case describes a 64-year-old male with hypertension who was initially prescribed antihypertensive therapy with olmesartan (OLM) once daily in the morning and amlodipine (AML) once daily in the evening. Reductions in blood pressure (BP) were observed, but BP control was not achieved. Therefore, an evening dose of hydrochlorothiazide (HCTZ) was added to the treatment regimen. Despite stating that he was adhering to therapy, the patient's prescription records indicated otherwise. The patient was switched to an OLM/AML/HCTZ single-pill fixed-dose combination and BP had decreased to the normal range at a follow-up visit 3 months later.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26173982     DOI: 10.1007/s40292-015-0109-0

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  9 in total

Review 1.  Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs.

Authors:  K O Stumpe; M Ludwig
Journal:  J Hum Hypertens       Date:  2002-05       Impact factor: 3.012

2.  Predictors of adherence with antihypertensive and lipid-lowering therapy.

Authors:  Richard H Chapman; Joshua S Benner; Allison A Petrilla; Jonothan C Tierce; S Robert Collins; David S Battleman; J Sanford Schwartz
Journal:  Arch Intern Med       Date:  2005-05-23

3.  Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  B J Materson; D J Reda; W C Cushman
Journal:  Am J Hypertens       Date:  1995-02       Impact factor: 2.689

4.  Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.

Authors:  David S Wald; Malcolm Law; Joan K Morris; Jonathan P Bestwick; Nicholas J Wald
Journal:  Am J Med       Date:  2009-03       Impact factor: 4.965

5.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.

Authors:  Bernard Vrijens; Gäbor Vincze; Paulus Kristanto; John Urquhart; Michel Burnier
Journal:  BMJ       Date:  2008-05-14

6.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redón; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

7.  Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension.

Authors:  Hans R Brunner; Klaus O Stumpe; Andrzej Januszewicz
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

8.  Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

Authors:  S Oparil; D Williams; S G Chrysant; T C Marbury; J Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Sep-Oct       Impact factor: 3.738

9.  Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.

Authors:  Thomas D Giles; Suzanne Oparil; Tonous N Silfani; Antonia Wang; J Findlay Walker
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-03       Impact factor: 3.738

  9 in total
  2 in total

Review 1.  The optimal blood pressure target in diabetes mellitus: a quest coming to an end?

Authors:  Eirini Papadopoulou; Elena Angeloudi; Spiridon Karras; Pantelis Sarafidis
Journal:  J Hum Hypertens       Date:  2018-06-22       Impact factor: 3.012

Review 2.  Formulations of Amlodipine: A Review.

Authors:  Muhammad Ali Sheraz; Syed Furqan Ahsan; Marium Fatima Khan; Sofia Ahmed; Iqbal Ahmad
Journal:  J Pharm (Cairo)       Date:  2016-10-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.